ClinicalTrials.gg
Not yet recruitingNCT07029464Updated Jun 19, 2025

Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis

An observational study in Robotic Surgical Procedures, Right Colon Tumors and Cancer, sponsored by The First Affiliated Hospital of Nanchang University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by The First Affiliated Hospital of Nanchang University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,000
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a retrospective, multicenter cohort study to compare short- and long-term outcomes between robotic and laparoscopic hemicolectomy of right colon cancer.

02

Conditions studied

  • Robotic Surgical Procedures
  • Right Colon Tumors
  • Cancer
  • Laparoscopic Abdominal Surgery

Browse trials for

Keywords

  • right colon cancer
  • robotic surgery
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

The First Affiliated Hospital of Nanchang University is the lead sponsor of 28 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The procedures were performed by 16 surgeons from 16 participating centers. Both primary surgeons and assistants completed standardized training in robotic and laparoscopic surgical techniques and obtained certification. Each center performs over 100 robotic- or laparoscopic-assisted radical right hemicolectomies annually. Primary surgeons had performed at least 50 cases of both robotic and laparoscopic-assisted radical right hemicolectomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Underwent radical right hemicolectomy by Da Vinci robotic or laparoscopic surgery 2.Postoperative pathology confirmed right colon adenocarcinoma (pT2-T4aNxM0; including cecal adenocarcinoma, ascending colon adenocarcinoma, hepatic flexure colon adenocarcinoma, and proximal transverse colon adenocarcinoma) 3.Complete clinical data and pathological results available

Exclusion criteria

Exclusion Criteria:

  • 1.Received therapy prior to surgery 2.History of other in the past 5 years (except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin) 3.Distant (e.g., liver, lung) or extensive abdominal/pelvic metastases confirmed by contrast-enhanced CT, PET-CT, or intraoperative exploration 4.Comorbid neurological/psychiatric disorders impairing ability to express 5.Poor systemic condition with to general anesthesia 6.Severe obesity ( >35 kg/m²) 7.Severe widespread abdominal adhesions precluding safe pneumoperitoneum establishment 8.Emergency surgery due to tumor perforation or obstruction 9.Refusal to provide informed consent
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • R Group

    robotic surgery

  • L Group

    Laparoscopic surgery

06

What researchers measure

Primary outcomes

  1. 3-year overall survival (OS) rate and 3-year disease-free survival (DFS) rate

    Time frame: (OS)From post-operation until death or the 3-year study endpoint (DFS)From post-operation to tumor recurrence or the 3-year study endpoint

Secondary outcomes

  1. Operative time

    Time frame: Periprocedural

  2. Intraoperative blood loss

    Time frame: Periprocedural

  3. Time to first flatus/bowel movement

    Time frame: Periprocedural

  4. Time to liquid diet initiation

    Time frame: Periprocedural

  5. Time to ambulation

    Time frame: Periprocedural

  6. Postoperative hospital stay duration

    Time frame: Up to 30 days

  7. Postoperative complications

    Surgery-related adverse events within 30 days, graded via the Clavien-Dindo classification system

    Time frame: From end of surgery to 30 days postoperatively

  8. Postoperative white blood cell (WBC) count

    Measured on postoperative days 1, 3, and 5

    Time frame: On postoperative days 1, 3, and 5

  9. Postoperative C-reactive protein (CRP) level

    Measured on postoperative days 1, 3, and 5

    Time frame: On postoperative days 1, 3, and 5

  10. Pain score

    Assessed using the Visual Analog Scale (VAS) on postoperative days 1, 3, and 5

    Time frame: On postoperative days 1, 3, and 5

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for May 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 19, 2025
StartEst.
Jun 2025
Primary completionEst.
May 2026
CompletionEst.
May 2027
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07029464
Lead sponsor
The First Affiliated Hospital of Nanchang University
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University Shanghai Cancer Center ( FUSCC ), The Second Affiliated Hospital of Harbin Medical University, Three Gorges Hospital of Chongqing University, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital of Zhengzhou University, Tianjin Third Central Hospital, Shandong University Second Hospital, Nanfang Hospital, Southern Medical University, Huadong Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Second Xiangya Hospital of Central South University, Jiangxi Provincial People's Hopital, Pingxiang People 's Hospital, Ganzhou City People's Hospital
Responsible party
Taiyuan Li (chief physician, The First Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Jun 19, 2025
Start date
Jun 2025 (estimated)
Primary completion
May 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jun 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion